Industrial emulsifiers such as carboxymethylcellulose erode the gut's protective mucus layer and drive inflammation and metabolic disease.
Original statement
والآليات لم تعد سرّاً: المستحلبات الصناعية كالكاربوكسي ميثيل سلولوز تُمزّق طبقة المخاط الواقية للأمعاء (Chassaing 2015 Nature).
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Industrial emulsifiers such as carboxymethylcellulose erode the gut's protective mucus layer and drive inflammation and metabolic disease.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (study selection and narrative are the archive's, not necessarily Elawady's)
- Origin
- https://eltayebat.com/rule/ultra-processed-foods/
- Attribution uncertainty
- The archive homepage states that the forbidden-food section is supported by research 'independently of Dr. Diaa's words'. No evidence was found that Elawady himself cited these studies.
- Claimed mechanism
Microbiota encroachment into mucus, low-grade inflammation.
- Claimed health effect
Colitis, metabolic syndrome, CVD, T2D.
- Population concerned
Humans (extrapolated from mice)
- Geographic restriction by Elawady
none found
Scientific assessment
Unclear / insufficient evidence – The data do not allow an assessment either way.
Certainty of evidence: low – Further research is likely to change the assessment considerably.
1. What was claimed?
Emulsifiers damage the gut barrier and cause disease.
2. What is demonstrably correct?
In mice, CMC and polysorbate 80 thinned the mucus layer, caused low-grade inflammation and metabolic syndrome, and colitis in susceptible strains (A-UPF-15). In a small human trial, 15 g/day CMC altered gut bacteria and metabolites (A-UPF-16). Some emulsifiers were associated with slightly more CVD and type 2 diabetes in a French cohort (I-UPF-04, I-UPF-05).
3. What is wrong or exaggerated?
Mucus erosion and inflammation are shown in mice, not in humans at usual intake. In a double-blind trial in people with active Crohn's disease, a high-emulsifier diet did not worsen disease activity compared with a low-emulsifier diet (I-UPF-114). In healthy adults a high-emulsifier diet caused no inflammation; gut permeability was lower at rest but higher under acute stress (I-UPF-113). The cohort associations are small (HRs about 1.03-1.11) and observational. 'Drive inflammation and metabolic disease' therefore overstates the human evidence.
4. What remains unclear?
Long-term effects of specific emulsifiers (e.g. CMC, polysorbate 80) at high intake, and effects in susceptible individuals.
5. Which studies support it?
A-UPF-15 (mice), A-UPF-16 (small human trial), I-UPF-04 and I-UPF-05 (cohort associations); I-UPF-113 partly (higher permeability under stress).
6. Which studies contradict it?
Fitzpatrick 2025 (I-UPF-114): no effect of emulsifier content on Crohn's disease activity over 4 weeks; Fitzpatrick 2024 (I-UPF-113): no inflammation in healthy adults; EFSA 2018 (I-UPF-121): no safety concern for celluloses including CMC at reported uses.
7. What applies to Germany and Europe?
EFSA has re-evaluated many emulsifiers; they remain authorised with conditions of use; regulators have not concluded on these newer findings in this review.
8. What is known about Egypt?
No Egypt-specific data.
9. What practical conclusion is appropriate?
Limiting heavily processed foods is reasonable for other reasons, but avoiding emulsifiers has not been shown to prevent or treat disease in humans.
Assessment details
- Rationale for certainty of evidence
Strong mouse experiments (A-UPF-15) and a tiny 11-day human trial with a high CMC dose (A-UPF-16) suggest harm; small cohort associations exist (I-UPF-04, I-UPF-05). However, two controlled human feeding trials at food-supply emulsifier levels found no gut inflammation in healthy adults (I-UPF-113) and no worsening of active Crohn's disease over 4 weeks (I-UPF-114), and EFSA found no safety concern for celluloses including CMC at reported uses (I-UPF-121). Human trials are small and short.
- Source quality
The archive generalises a mouse finding to humans ('mechanisms are no longer mysterious').
- Regional transferability
High for EU: CMC (E466) and other emulsifiers are authorised under Reg. 1333/2008.
- Individual exceptions
Not applicable.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).
Research question: In humans, do dietary emulsifiers such as carboxymethylcellulose, at usual intake, erode the intestinal mucus layer and cause intestinal inflammation and metabolic disease?
Research question in detail (PICO)
- Population
- Humans (healthy and with Crohn's disease); animal models as background
- Intervention or exposure
- Dietary emulsifiers (CMC, polysorbate 80, others)
- Comparison
- Low-emulsifier diet / placebo
- Geographic scope
- universal biology
- Outcomes
- Gut barrier and mucus
- Intestinal inflammation / disease activity
- Cardiometabolic disease
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Emulsifiers and gut inflammation in mice
Chassaing B et al.. Nature 2015 · PMID 25731162 · DOI 10.1038/nature14232 Animal studyfull text, structured risk-of-bias assessmentMouse study: CMC and P80 thinned mucus, caused low-grade inflammation, colitis (susceptible mice) and metabolic syndrome.
- Actual result
- Bacteria-epithelium distance reduced >50%.
- Methodological quality
- high-quality animal study
- Relevance
- very indirect (mice)
- Limitations
- Doses 0.1-1% of diet.
Emulsifier CMC in a small human trial
Chassaing B et al.. Gastroenterology 2022 · PMID 34774538 · DOI 10.1053/j.gastro.2021.11.006 Randomised controlled trialabstract checkedHuman feeding RCT: 15 g/day CMC altered microbiota and metabolome; encroachment in 2 of 7.
- Actual result
- n=16; 11 days.
- Methodological quality
- low (tiny, short, high dose)
- Relevance
- direct
Emulsifiers and heart disease in France
Sellem L et al.. BMJ 2023 · PMID 37673430 · DOI 10.1136/bmj-2023-076058 Cohort studyfull text, structured risk-of-bias assessmentNutriNet-Sante: some emulsifiers associated with CVD.
- Actual result
- Per SD HRs 1.03-1.08.
- Methodological quality
- moderate (cohort)
- Relevance
- indirect
- Limitations
- Small; several not significant after FDR.
What speaks against the claim?
Emulsifiers in people with Crohn's disease
Fitzpatrick JA et al.. Aliment Pharmacol Ther 2025 · PMID 39967287 · DOI 10.1111/apt.70041 Randomised controlled trialabstract checkednewly addedDouble-blind RCT in active Crohn's disease: high vs low emulsifier diet made no difference over 4 weeks.
- Actual result
- Remission 9/12 vs 7/12; no significant differences.
- Methodological quality
- moderate (small exploratory RCT)
- Relevance
- direct (most susceptible group)
- Limitations
- n=24; 4 weeks.
Emulsifiers and the gut barrier in healthy people
Fitzpatrick JA et al.. Aliment Pharmacol Ther 2024 · PMID 39072856 · DOI 10.1111/apt.18172 Randomised controlled trialabstract checkednewly addedRCT in healthy adults: high-emulsifier diet caused no inflammation; barrier better at rest, more permeable under stress.
- Actual result
- LRR 0.030 vs 0.042 at rest.
- Methodological quality
- moderate
- Relevance
- direct
- Limitations
- n=22; surrogate.
EU safety review of cellulose additives (including CMC)
EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) et al.. EFSA J 2018 · PMID 32625652 · DOI 10.2903/j.efsa.2018.5047 Risk assessmentabstract checkednewly addedEFSA 2018: no safety concern for celluloses including CMC at reported uses.
- Actual result
- No toxicity at high doses in animals.
- Methodological quality
- high (regulatory)
- Relevance
- indirect
- Limitations
- Microbiome endpoints not decisive.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Clear harm in mice; in humans, small controlled trials at realistic intakes found no inflammation or worsening of Crohn's disease, while cohort data show small associations.
Why some studies weigh more
Direct human RCTs at realistic intake weigh more than mouse experiments for the human claim, but they are small and short.
Is a causal relationship established? Not established Animal → human extrapolation not confirmed in human trials.
Remaining uncertainty
Long-term effects; specific emulsifiers (CMC, P80) at high intake; susceptible individuals.
Justified conclusion
Plausible concern, not established human harm at usual intake.
Why do studies seem to disagree?
Mice (high dose, specific emulsifiers, weeks) vs human feeding trials (food-supply levels, mixtures, 4 weeks): different doses, species and endpoints.
Does this depend on the country?
- General biological effects
- Gut biology similar, but mouse-to-human transfer uncertain.
- Eating habits
- Emulsifier intake depends on UPF consumption.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Formulations differ.
- Legal rules
- CMC (E 466) authorised in EU (I-UPF-121); Egyptian status not verified.
- Actual monitoring data
- None.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Power – Exploratory n=24; differences not significant; no recalculation possible from abstract. not recalculable from the published data
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Intestinal inflammation from emulsifiers at usual intake in humans
- Starting level
- high (randomised trials)
- Reasons for downgrading
- imprecision (small trials)
- indirectness (short duration; animal data)
- Result
- low
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | (TITLE:emulsifier* OR TITLE:carboxymethylcellulose OR TITLE:polysorbate) AND (TITLE:human OR TITLE:randomized OR TITLE:randomised OR TITLE:trial OR TITLE:"Crohn" OR TITLE:diet) AND PUB_YEAR:[2020 TO 2026] | both directions | 55 | |
| Europe PMC | 26 October 2026 | (TITLE:"re-evaluation" OR TITLE:"reevaluation") AND (TITLE:cellulose OR TITLE:"E 466" OR TITLE:polysorbates OR TITLE:"E 433") AND JOURNAL:"EFSA J" | contradicting evidence | 3 |
How deeply was this checked?
7 linked studies: 2 checked in full text (2 of them with a structured risk-of-bias assessment), 5 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Potentially true (low)
- 26 October 2026 · Phase 4 (systematic evidence review) · Verdict changed: Potentially true (low) → Unclear / insufficient evidence (low)
Two direct human RCTs (healthy adults and Crohn's disease) at realistic food-supply emulsifier levels found no inflammation or disease worsening, and EFSA found no safety concern for CMC. Previously the review stated that no contradicting evidence existed; with direct null human trials, the balance moves from 'plausibly true' to 'unclear'.
New sources: I-UPF-113 I-UPF-114 I-UPF-121
In plain language
In mice, two common emulsifiers damaged the protective gut lining and caused inflammation and weight gain. In people, the evidence is different: in small, carefully controlled trials, normal amounts of emulsifiers did not inflame the gut of healthy adults and did not worsen Crohn's disease. European food-safety experts found no safety concern for these additives at current use. Whether emulsifiers harm humans in the long run is unclear.
Studies on this claim
Studies supporting the claim (4)
-
Emulsifiers and gut inflammation in mice
Chassaing B et al.. Nature 2015 · PMID 25731162 · DOI 10.1038/nature14232Animal studycited by the Tayebat archivefull text, structured risk-of-bias assessment★ key studyTwo common emulsifiers caused gut inflammation and metabolic problems in mice.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Do emulsifiers promote gut inflammation and metabolic syndrome via microbiota?
- How was the study done?
Mouse experiments with emulsifiers, germ-free mice and faecal transplants.
- How many people, animals or samples were studied?
Not stated; Wild-type and colitis-prone mice
- What was actually found?
Emulsifiers induced low-grade inflammation and obesity/metabolic syndrome in wild-type mice and robust colitis in predisposed mice; microbiota encroachment; effects transferable via microbiota.
- How large was the observed effect?
Not applicable
- What do the results mean in everyday life?
Possible concern for humans, not proven.
- What are the study's limitations?
Mouse study only; doses of 0.1-1% in all food or water; the researchers knew which mice got which treatment; some groups very small; only two emulsifiers tested.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
It cannot show that emulsifiers cause bowel inflammation or weight gain in humans, or at what human intake level any effect would occur.
-
Emulsifier CMC in a small human trial
Chassaing B et al.. Gastroenterology 2022 · PMID 34774538 · DOI 10.1053/j.gastro.2021.11.006Randomised controlled trialcited by the Tayebat archiveabstract checkedSeven people eating CMC for 11 days had changes in gut bacteria and mild discomfort.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does CMC affect the gut in healthy humans?
- How was the study done?
Double-blind controlled feeding study, 11 days.
- How many people, animals or samples were studied?
16 (9 control, 7 CMC); Healthy adults
- What was actually found?
CMC modestly increased postprandial abdominal discomfort, reduced microbiota diversity, reduced faecal SCFAs and free amino acids; 2 CMC subjects showed microbiota encroachment into inner mucus.
- How large was the observed effect?
Not applicable
- What do the results mean in everyday life?
Early human signal.
- What are the study's limitations?
Very small; Short; High dose; Surrogate outcomes
- What does it say about Elawady's specific claim?
Supports C-UPF-06.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Disease risk.
-
Emulsifiers and heart disease in France
Sellem L et al.. BMJ 2023 · PMID 37673430 · DOI 10.1136/bmj-2023-076058Cohort studyindependent cross-checkfull text, structured risk-of-bias assessment★ key studyHigher intake of some emulsifiers, including CMC, was linked with slightly more heart disease.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Are emulsifier intakes associated with CVD?
- How was the study done?
Prospective cohort with additive exposure estimation.
- How many people, animals or samples were studied?
95,442; 1,995 CVD events; Adults without CVD, 79% women
- What was actually found?
Celluloses (E460-E468) CVD HR 1.05 (1.02-1.09), CHD 1.07; CMC (E466) CVD 1.03 (1.01-1.05), CHD 1.04; E471/E472 associated with all outcomes; E472b cerebrovascular 1.11; trisodium phosphate CHD 1.06.
- How large was the observed effect?
HR 1.03-1.11 per SD
- What do the results mean in everyday life?
Small possible effect.
- What are the study's limitations?
One French cohort of mostly women volunteers; associations are very small and some disappear after correction for multiple testing; most emulsifiers studied showed no link; additive intake was estimated, not measured in blood or urine.
- What does it say about Elawady's specific claim?
Supports C-UPF-06 weakly.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
It cannot show that emulsifiers cause heart disease, nor that they erode the gut mucus in people; it does not provide absolute risks.
-
Emulsifiers and diabetes in France
Salame C et al.. Lancet Diabetes Endocrinol 2024 · PMID 38663950 · DOI 10.1016/S2213-8587(24)00086-XCohort studyindependent cross-checkabstract checkedSeveral emulsifiers were linked with slightly higher diabetes risk.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Are emulsifiers associated with T2D?
- How was the study done?
Prospective cohort with time-dependent additive exposure.
- How many people, animals or samples were studied?
104,139; 1,056 T2D cases; Adults, 79% women
- What was actually found?
Carrageenans HR 1.03 per 100 mg/day; tripotassium phosphate 1.15 per 500 mg/day; E472e 1.04; sodium citrate 1.04; guar gum 1.11; gum arabic 1.03; xanthan gum 1.08.
- How large was the observed effect?
HR 1.03-1.15 per increment
- What do the results mean in everyday life?
Small possible effect.
- What are the study's limitations?
Single cohort; Multiple testing; Observational design; residual confounding possible; Self-reported dietary intake
- What does it say about Elawady's specific claim?
Supports C-UPF-06 weakly.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Causation.
No study in this group is marked as key.
Studies contradicting or limiting the claim (2)
-
Emulsifiers in people with Crohn's disease
Fitzpatrick JA et al.. Aliment Pharmacol Ther 2025 · PMID 39967287 · DOI 10.1111/apt.70041Randomised controlled trialindependent cross-checkabstract checkedIn a small blinded trial, a diet high in food emulsifiers did not worsen Crohn's disease over four weeks compared with a low-emulsifier diet.
No effect of high vs low emulsifier diet on Crohn's disease activity over 4 weeks.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
To test whether food emulsifiers worsen Crohn's disease.
- How was the study done?
Double-blinded randomised feeding trial.
- How many people, animals or samples were studied?
24 patients.
- What was actually found?
No difference between diets; both improved.
- How large was the observed effect?
Remission 9/12 vs 7/12.
- What do the results mean in everyday life?
Avoiding emulsifiers is not proven to help Crohn's disease.
- What are the study's limitations?
Small and short.
- What does it say about Elawady's specific claim?
Contradicts C-UPF-06 in humans.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Cannot exclude long-term or dose-specific effects.
-
EU safety review of cellulose additives (including CMC)
EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) et al.. EFSA J 2018 · PMID 32625652 · DOI 10.2903/j.efsa.2018.5047Risk assessmentindependent cross-checkabstract checkedEFSA found no safety concern for cellulose additives such as carboxymethylcellulose at the levels used in food.
EFSA 2018: no safety concern for celluloses including CMC (E 466) at reported uses.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
To re-evaluate cellulose food additives.
- How was the study done?
Regulatory risk assessment.
- How many people, animals or samples were studied?
Not applicable.
- What was actually found?
No toxicity concerns at reported uses.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Authorities consider CMC safe at current levels.
- What are the study's limitations?
Mainly animal toxicology; microbiome data not decisive.
- What does it say about Elawady's specific claim?
Contradicts C-UPF-06.
- Do the results apply to Germany and Europe?
EU.
- What can explicitly not be concluded from this study?
Cannot exclude subtle gut effects.
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Emulsifiers and the gut barrier in healthy people
Fitzpatrick JA et al.. Aliment Pharmacol Ther 2024 · PMID 39072856 · DOI 10.1111/apt.18172Randomised controlled trialindependent cross-checkabstract checkedA diet high in common food emulsifiers did not cause gut inflammation; the gut barrier was tighter at rest but leakier under stress.
No inflammation; barrier better at rest but more permeable under acute stress with high-emulsifier diet.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
To test emulsifiers on the human gut barrier.
- How was the study done?
Randomised crossover feeding trial.
- How many people, animals or samples were studied?
22 healthy adults.
- What was actually found?
No inflammation; mixed barrier effects.
- How large was the observed effect?
Permeability ratio 0.030 vs 0.042 (rest).
- What do the results mean in everyday life?
Normal emulsifier intake did not inflame the gut in this short trial.
- What are the study's limitations?
Very small; surrogate markers.
- What does it say about Elawady's specific claim?
Mixed for C-UPF-06.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Cannot show long-term safety or harm.
No study in this group is marked as key.
Regional context
Germany / EU
EFSA has re-evaluated many emulsifiers; they remain authorised with conditions of use; regulators have not concluded on these newer findings in this review.
Egypt
No Egypt-specific data.
What applies in my country?
General scientific assessment
Unclear / insufficient evidence Unclear: emulsifiers harmed the gut in mice, but small human trials at normal intake found no inflammation or disease worsening.
The following areas of food safety are relevant to this statement:
- Additives and processing
- Controls, imports, recalls, labelling
Choose a country to see the checked information for it.
Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.
Country of residence or purchase Compare with another country
References
- Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome.. Chassaing B et al.. Nature 2015 · PMID 25731162 · DOI 10.1038/nature14232
- Randomized Controlled-Feeding Study of Dietary Emulsifier Carboxymethylcellulose Reveals Detrimental Impacts on the Gut Microbiota and Metabolome.. Chassaing B et al.. Gastroenterology 2022 · PMID 34774538 · DOI 10.1053/j.gastro.2021.11.006
- Food additive emulsifiers and risk of cardiovascular disease in the NutriNet-Santé cohort: prospective cohort study.. Sellem L et al.. BMJ 2023 · PMID 37673430 · DOI 10.1136/bmj-2023-076058
- Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort study.. Salame C et al.. Lancet Diabetes Endocrinol 2024 · PMID 38663950 · DOI 10.1016/S2213-8587(24)00086-X
- Clinical Trial: The Effects of Emulsifiers in the Food Supply on Disease Activity in Crohn's Disease: An Exploratory Double-Blinded Randomised Feeding Trial.. Fitzpatrick JA et al.. Aliment Pharmacol Ther 2025 · PMID 39967287 · DOI 10.1111/apt.70041
- Re-evaluation of celluloses E 460(i), E 460(ii), E 461, E 462, E 463, E 464, E 465, E 466, E 468 and E 469 as food additives.. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) et al.. EFSA J 2018 · PMID 32625652 · DOI 10.2903/j.efsa.2018.5047
- The effect of dietary emulsifiers and thickeners on intestinal barrier function and its response to acute stress in healthy adult humans: A randomised controlled feeding study.. Fitzpatrick JA et al.. Aliment Pharmacol Ther 2024 · PMID 39072856 · DOI 10.1111/apt.18172